William Fantegrossi
Concepts (322)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
N-Methyl-3,4-methylenedioxyamphetamine | 20 | 2024 | 38 | 6.550 |
Why?
| Cannabinoids | 15 | 2022 | 105 | 4.290 |
Why?
| Central Nervous System Stimulants | 14 | 2023 | 213 | 4.270 |
Why?
| Hallucinogens | 17 | 2023 | 62 | 4.160 |
Why?
| Pyrrolidines | 10 | 2020 | 83 | 4.150 |
Why?
| Benzodioxoles | 9 | 2020 | 56 | 4.130 |
Why?
| Motor Activity | 14 | 2024 | 229 | 3.690 |
Why?
| Conditioning, Operant | 13 | 2024 | 116 | 3.620 |
Why?
| Receptor, Cannabinoid, CB1 | 15 | 2022 | 125 | 3.550 |
Why?
| Locomotion | 9 | 2024 | 92 | 3.500 |
Why?
| Indoles | 17 | 2022 | 278 | 3.090 |
Why?
| Naphthalenes | 13 | 2022 | 121 | 2.960 |
Why?
| Behavior, Animal | 16 | 2016 | 181 | 2.940 |
Why?
| Animals | 69 | 2024 | 13187 | 2.410 |
Why?
| Substance-Related Disorders | 11 | 2024 | 600 | 2.220 |
Why?
| Mice | 42 | 2024 | 5739 | 2.110 |
Why?
| Cannabinoid Receptor Agonists | 9 | 2022 | 49 | 2.090 |
Why?
| Dose-Response Relationship, Drug | 26 | 2023 | 1376 | 2.050 |
Why?
| Body Temperature Regulation | 4 | 2020 | 24 | 1.900 |
Why?
| Discrimination Learning | 6 | 2020 | 64 | 1.800 |
Why?
| Designer Drugs | 6 | 2016 | 28 | 1.760 |
Why?
| Alkaloids | 5 | 2023 | 32 | 1.730 |
Why?
| Indazoles | 7 | 2022 | 47 | 1.590 |
Why?
| Temperature | 3 | 2023 | 168 | 1.580 |
Why?
| Cocaine | 7 | 2020 | 170 | 1.550 |
Why?
| Phencyclidine | 2 | 2024 | 38 | 1.530 |
Why?
| Amphetamines | 4 | 2023 | 29 | 1.500 |
Why?
| Rats, Sprague-Dawley | 9 | 2024 | 1597 | 1.470 |
Why?
| Impulsive Behavior | 2 | 2020 | 77 | 1.340 |
Why?
| Receptor, Serotonin, 5-HT2A | 6 | 2014 | 12 | 1.330 |
Why?
| Male | 46 | 2024 | 25241 | 1.330 |
Why?
| Receptor, Cannabinoid, CB2 | 5 | 2018 | 58 | 1.310 |
Why?
| Drug Tolerance | 3 | 2019 | 60 | 1.290 |
Why?
| Rats | 17 | 2024 | 3305 | 1.230 |
Why?
| Dopamine | 7 | 2019 | 171 | 1.160 |
Why?
| Methamphetamine | 8 | 2020 | 200 | 1.110 |
Why?
| Telemetry | 4 | 2020 | 32 | 1.050 |
Why?
| Serotonin | 4 | 2018 | 152 | 1.040 |
Why?
| Valine | 3 | 2022 | 58 | 1.030 |
Why?
| Dopamine Uptake Inhibitors | 4 | 2020 | 56 | 1.020 |
Why?
| Naltrexone | 4 | 2021 | 58 | 1.000 |
Why?
| Head Movements | 2 | 2014 | 6 | 0.980 |
Why?
| Phenethylamines | 4 | 2014 | 8 | 0.960 |
Why?
| Hypothermia | 2 | 2022 | 35 | 0.920 |
Why?
| Self Administration | 11 | 2020 | 102 | 0.910 |
Why?
| Serotonin 5-HT2 Receptor Agonists | 4 | 2021 | 8 | 0.900 |
Why?
| Avoidance Learning | 2 | 2014 | 17 | 0.880 |
Why?
| Tryptamines | 3 | 2014 | 9 | 0.870 |
Why?
| Convulsants | 2 | 2022 | 7 | 0.870 |
Why?
| Psychoses, Substance-Induced | 2 | 2024 | 9 | 0.860 |
Why?
| Cyclohexylamines | 2 | 2024 | 7 | 0.840 |
Why?
| Receptors, Opioid, mu | 4 | 2018 | 46 | 0.810 |
Why?
| Cannabinoid Receptor Antagonists | 3 | 2020 | 17 | 0.800 |
Why?
| Piperidines | 11 | 2014 | 98 | 0.800 |
Why?
| Quinuclidines | 2 | 2019 | 40 | 0.790 |
Why?
| Serotonin Agents | 5 | 2020 | 15 | 0.790 |
Why?
| Choice Behavior | 2 | 2019 | 85 | 0.770 |
Why?
| Laboratories | 1 | 2021 | 21 | 0.770 |
Why?
| Seizures | 3 | 2022 | 195 | 0.770 |
Why?
| Neurotransmitter Uptake Inhibitors | 2 | 2018 | 7 | 0.760 |
Why?
| Body Temperature | 7 | 2017 | 69 | 0.750 |
Why?
| Biogenic Monoamines | 3 | 2017 | 13 | 0.730 |
Why?
| Alcoholism | 2 | 2021 | 232 | 0.720 |
Why?
| Stereotyped Behavior | 1 | 2019 | 17 | 0.700 |
Why?
| Receptors, Opioid, delta | 2 | 2018 | 26 | 0.690 |
Why?
| Alcohol Drinking | 1 | 2021 | 224 | 0.680 |
Why?
| Adamantane | 4 | 2020 | 25 | 0.670 |
Why?
| Serotonin Antagonists | 7 | 2009 | 34 | 0.670 |
Why?
| Ethanol | 2 | 2021 | 340 | 0.670 |
Why?
| Enzyme Inhibitors | 3 | 2019 | 391 | 0.660 |
Why?
| Glutamic Acid | 2 | 2018 | 107 | 0.650 |
Why?
| Dopamine Plasma Membrane Transport Proteins | 3 | 2023 | 44 | 0.630 |
Why?
| Analgesics, Opioid | 5 | 2018 | 552 | 0.630 |
Why?
| Drug Interactions | 5 | 2021 | 206 | 0.620 |
Why?
| Vaccination | 1 | 2020 | 266 | 0.620 |
Why?
| Stereoisomerism | 10 | 2016 | 104 | 0.620 |
Why?
| Morphine Derivatives | 1 | 2018 | 29 | 0.620 |
Why?
| Fever | 2 | 2017 | 114 | 0.610 |
Why?
| Cyclohexanones | 1 | 2017 | 7 | 0.600 |
Why?
| Fluorobenzenes | 7 | 2014 | 21 | 0.560 |
Why?
| Cannabis | 1 | 2019 | 145 | 0.560 |
Why?
| Brain Chemistry | 2 | 2007 | 70 | 0.540 |
Why?
| Receptor, Serotonin, 5-HT2C | 3 | 2010 | 6 | 0.490 |
Why?
| Visceral Pain | 1 | 2014 | 2 | 0.480 |
Why?
| Morphine Dependence | 1 | 2014 | 11 | 0.480 |
Why?
| Appetite | 1 | 2014 | 17 | 0.480 |
Why?
| Disease Models, Animal | 5 | 2023 | 1455 | 0.470 |
Why?
| Aporphines | 3 | 2016 | 6 | 0.460 |
Why?
| Reinforcement Schedule | 4 | 2020 | 78 | 0.460 |
Why?
| Structure-Activity Relationship | 5 | 2023 | 395 | 0.440 |
Why?
| Substance Withdrawal Syndrome | 3 | 2019 | 169 | 0.440 |
Why?
| Fenclonine | 2 | 2017 | 7 | 0.420 |
Why?
| Physical Conditioning, Animal | 1 | 2012 | 52 | 0.410 |
Why?
| p-Chloroamphetamine | 1 | 2011 | 3 | 0.400 |
Why?
| Humans | 28 | 2023 | 49974 | 0.400 |
Why?
| Macaca mulatta | 8 | 2011 | 93 | 0.400 |
Why?
| Microsomes, Liver | 4 | 2020 | 186 | 0.390 |
Why?
| Brain | 8 | 2020 | 1328 | 0.390 |
Why?
| Pain | 2 | 2013 | 379 | 0.380 |
Why?
| Receptor, Serotonin, 5-HT1A | 2 | 2007 | 4 | 0.370 |
Why?
| Head | 1 | 2010 | 73 | 0.360 |
Why?
| Movement | 1 | 2010 | 82 | 0.360 |
Why?
| Receptors, Serotonin | 3 | 2007 | 29 | 0.340 |
Why?
| Narcotic Antagonists | 4 | 2018 | 135 | 0.330 |
Why?
| Ketanserin | 4 | 2014 | 9 | 0.290 |
Why?
| Random Allocation | 2 | 2020 | 281 | 0.280 |
Why?
| Crowding | 2 | 2004 | 14 | 0.280 |
Why?
| Chromatography, High Pressure Liquid | 4 | 2020 | 349 | 0.270 |
Why?
| Microglia | 1 | 2007 | 141 | 0.270 |
Why?
| Serotonin Receptor Agonists | 1 | 2005 | 14 | 0.270 |
Why?
| Diterpenes | 1 | 2005 | 31 | 0.260 |
Why?
| Receptors, Opioid, kappa | 1 | 2005 | 39 | 0.260 |
Why?
| Neurotoxicity Syndromes | 1 | 2006 | 46 | 0.260 |
Why?
| Psychotropic Drugs | 1 | 2005 | 77 | 0.260 |
Why?
| Cognition | 2 | 2024 | 338 | 0.250 |
Why?
| Phencyclidine Abuse | 1 | 2024 | 2 | 0.240 |
Why?
| Tetrabenazine | 1 | 2004 | 12 | 0.240 |
Why?
| Opioid-Related Disorders | 2 | 2019 | 381 | 0.240 |
Why?
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2023 | 10 | 0.230 |
Why?
| Receptors, Cannabinoid | 2 | 2014 | 19 | 0.230 |
Why?
| Ketamine | 1 | 2024 | 60 | 0.230 |
Why?
| Amphetamine-Related Disorders | 2 | 2020 | 94 | 0.230 |
Why?
| Binding, Competitive | 4 | 2013 | 94 | 0.230 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2023 | 47 | 0.230 |
Why?
| Reaction Time | 3 | 2018 | 216 | 0.220 |
Why?
| Lysergic Acid Diethylamide | 3 | 2007 | 6 | 0.220 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 89 | 0.220 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 2 | 2014 | 9 | 0.220 |
Why?
| Social Isolation | 1 | 2003 | 28 | 0.220 |
Why?
| Cytochrome P-450 CYP3A | 2 | 2020 | 78 | 0.210 |
Why?
| Pentylenetetrazole | 1 | 2022 | 9 | 0.210 |
Why?
| Diazepam | 1 | 2022 | 17 | 0.210 |
Why?
| Analysis of Variance | 2 | 2017 | 562 | 0.210 |
Why?
| Tremor | 1 | 2022 | 11 | 0.210 |
Why?
| Fluoxetine | 2 | 2017 | 42 | 0.200 |
Why?
| Amides | 1 | 2022 | 34 | 0.200 |
Why?
| Carrier Proteins | 1 | 2023 | 304 | 0.200 |
Why?
| Benzodiazepines | 1 | 2022 | 70 | 0.200 |
Why?
| Rats, Long-Evans | 1 | 2021 | 26 | 0.200 |
Why?
| Alcohol Deterrents | 1 | 2021 | 8 | 0.200 |
Why?
| Housing, Animal | 1 | 2021 | 15 | 0.190 |
Why?
| Central Nervous System Depressants | 1 | 2021 | 79 | 0.190 |
Why?
| Electroencephalography | 1 | 2022 | 306 | 0.180 |
Why?
| Artificial Gene Fusion | 1 | 2020 | 7 | 0.180 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2020 | 11 | 0.180 |
Why?
| Microsomes | 1 | 2020 | 35 | 0.180 |
Why?
| Spiro Compounds | 2 | 2010 | 8 | 0.180 |
Why?
| Single-Chain Antibodies | 1 | 2020 | 21 | 0.180 |
Why?
| Adrenergic Uptake Inhibitors | 1 | 2019 | 15 | 0.180 |
Why?
| Rodentia | 1 | 2020 | 18 | 0.170 |
Why?
| Psychopharmacology | 1 | 2019 | 5 | 0.170 |
Why?
| Corpus Striatum | 1 | 2019 | 50 | 0.170 |
Why?
| GTP-Binding Proteins | 2 | 2017 | 90 | 0.170 |
Why?
| Molecular Structure | 5 | 2014 | 297 | 0.170 |
Why?
| Catalepsy | 1 | 2019 | 9 | 0.170 |
Why?
| Genetic Therapy | 1 | 2020 | 114 | 0.170 |
Why?
| Nociception | 1 | 2019 | 13 | 0.170 |
Why?
| Morpholines | 2 | 2017 | 71 | 0.160 |
Why?
| Taste | 1 | 2018 | 33 | 0.160 |
Why?
| Cytochrome P-450 Enzyme System | 2 | 2017 | 195 | 0.160 |
Why?
| Time Factors | 2 | 2019 | 2903 | 0.160 |
Why?
| alpha-Methyltyrosine | 1 | 2017 | 5 | 0.150 |
Why?
| Fetus | 1 | 2019 | 217 | 0.150 |
Why?
| Propiophenones | 1 | 2017 | 3 | 0.150 |
Why?
| Phthalimides | 1 | 2017 | 4 | 0.150 |
Why?
| Reproducibility of Results | 1 | 2021 | 1193 | 0.150 |
Why?
| Animals, Newborn | 2 | 2019 | 367 | 0.150 |
Why?
| Buprenorphine | 1 | 2019 | 140 | 0.140 |
Why?
| Benzoxazines | 1 | 2017 | 18 | 0.140 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2019 | 186 | 0.140 |
Why?
| Data Interpretation, Statistical | 2 | 2007 | 158 | 0.140 |
Why?
| Mice, Inbred Strains | 3 | 2012 | 161 | 0.140 |
Why?
| Oxidation-Reduction | 4 | 2020 | 322 | 0.140 |
Why?
| Positron-Emission Tomography | 2 | 2009 | 295 | 0.140 |
Why?
| Tandem Mass Spectrometry | 3 | 2014 | 236 | 0.140 |
Why?
| Rats, Inbred F344 | 2 | 2007 | 196 | 0.140 |
Why?
| Serotonin 5-HT1 Receptor Agonists | 1 | 2016 | 6 | 0.140 |
Why?
| Blood-Brain Barrier | 1 | 2016 | 48 | 0.140 |
Why?
| Recombinant Proteins | 4 | 2020 | 486 | 0.130 |
Why?
| Schizophrenia | 1 | 2018 | 256 | 0.130 |
Why?
| Marijuana Abuse | 1 | 2018 | 147 | 0.130 |
Why?
| Cerebral Cortex | 2 | 2007 | 200 | 0.130 |
Why?
| Blood Pressure | 1 | 2018 | 512 | 0.130 |
Why?
| Psychomotor Performance | 2 | 2013 | 130 | 0.120 |
Why?
| Endothelial Cells | 1 | 2016 | 269 | 0.120 |
Why?
| Antipsychotic Agents | 1 | 2016 | 232 | 0.120 |
Why?
| Urinalysis | 1 | 2014 | 34 | 0.120 |
Why?
| Fentanyl | 1 | 2014 | 36 | 0.110 |
Why?
| Membranes | 1 | 2013 | 17 | 0.110 |
Why?
| Memory | 2 | 2011 | 116 | 0.110 |
Why?
| Drug Synergism | 1 | 2013 | 150 | 0.110 |
Why?
| Metabolomics | 1 | 2013 | 126 | 0.100 |
Why?
| Pain Measurement | 1 | 2013 | 240 | 0.100 |
Why?
| Adrenergic Agents | 1 | 2011 | 15 | 0.100 |
Why?
| Female | 8 | 2020 | 26472 | 0.100 |
Why?
| Kinetics | 3 | 2020 | 623 | 0.100 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2011 | 11 | 0.100 |
Why?
| Pyrazoles | 1 | 2012 | 113 | 0.100 |
Why?
| Oxalates | 1 | 2011 | 12 | 0.100 |
Why?
| Analgesics, Non-Narcotic | 1 | 2012 | 117 | 0.100 |
Why?
| Receptors, sigma | 1 | 2011 | 16 | 0.090 |
Why?
| Ethylamines | 1 | 2010 | 3 | 0.090 |
Why?
| Linear Models | 1 | 2011 | 280 | 0.090 |
Why?
| Aminopyridines | 1 | 2010 | 15 | 0.090 |
Why?
| Cricetulus | 3 | 2017 | 97 | 0.090 |
Why?
| CHO Cells | 3 | 2017 | 120 | 0.090 |
Why?
| Amphetamine | 1 | 2010 | 38 | 0.090 |
Why?
| Tissue Distribution | 2 | 2013 | 163 | 0.090 |
Why?
| Models, Animal | 2 | 2011 | 233 | 0.090 |
Why?
| Saimiri | 1 | 2009 | 2 | 0.090 |
Why?
| Nortropanes | 1 | 2009 | 2 | 0.090 |
Why?
| Cells, Cultured | 1 | 2013 | 1573 | 0.090 |
Why?
| Electrochemical Techniques | 1 | 2009 | 11 | 0.080 |
Why?
| Tropanes | 1 | 2009 | 4 | 0.080 |
Why?
| Sulfonamides | 1 | 2010 | 129 | 0.080 |
Why?
| Microdialysis | 1 | 2009 | 18 | 0.080 |
Why?
| Fluorine Radioisotopes | 1 | 2009 | 24 | 0.080 |
Why?
| Receptors, Opioid | 1 | 2009 | 18 | 0.080 |
Why?
| Food | 1 | 2009 | 72 | 0.080 |
Why?
| Polymorphism, Genetic | 2 | 2020 | 181 | 0.080 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2009 | 244 | 0.080 |
Why?
| Imidazoles | 1 | 2009 | 119 | 0.080 |
Why?
| Neostriatum | 1 | 2007 | 10 | 0.080 |
Why?
| Isoquinolines | 1 | 2007 | 25 | 0.080 |
Why?
| Primates | 1 | 2007 | 20 | 0.070 |
Why?
| Ligands | 3 | 2013 | 204 | 0.070 |
Why?
| Cocaine-Related Disorders | 1 | 2009 | 205 | 0.070 |
Why?
| Piperazines | 1 | 2007 | 117 | 0.070 |
Why?
| Pyridines | 1 | 2007 | 130 | 0.070 |
Why?
| Injections, Intravenous | 1 | 2006 | 140 | 0.070 |
Why?
| Generalization, Stimulus | 1 | 2005 | 5 | 0.070 |
Why?
| Diterpenes, Clerodane | 1 | 2005 | 20 | 0.070 |
Why?
| Benzeneacetamides | 1 | 2005 | 13 | 0.070 |
Why?
| Premedication | 1 | 2005 | 21 | 0.070 |
Why?
| Racemases and Epimerases | 1 | 2005 | 15 | 0.070 |
Why?
| Injections, Intraperitoneal | 1 | 2005 | 54 | 0.070 |
Why?
| Naloxone | 1 | 2005 | 78 | 0.060 |
Why?
| Body Weight | 1 | 2007 | 513 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2018 | 408 | 0.060 |
Why?
| Cognition Disorders | 1 | 2006 | 218 | 0.060 |
Why?
| Protein Binding | 2 | 2020 | 660 | 0.060 |
Why?
| Tritium | 1 | 2004 | 47 | 0.060 |
Why?
| Electrochemistry | 1 | 2004 | 26 | 0.060 |
Why?
| Radioligand Assay | 1 | 2004 | 46 | 0.060 |
Why?
| Tomography, Emission-Computed | 1 | 2004 | 53 | 0.060 |
Why?
| Prazosin | 1 | 2004 | 10 | 0.060 |
Why?
| Biomedical Research | 1 | 2007 | 237 | 0.060 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2004 | 27 | 0.060 |
Why?
| Infusions, Intravenous | 1 | 2004 | 206 | 0.060 |
Why?
| ROC Curve | 1 | 2004 | 232 | 0.060 |
Why?
| Lethal Dose 50 | 1 | 2003 | 12 | 0.050 |
Why?
| Drug Inverse Agonism | 2 | 2013 | 18 | 0.050 |
Why?
| Brain Mapping | 1 | 2004 | 235 | 0.050 |
Why?
| Cold Temperature | 1 | 2003 | 44 | 0.050 |
Why?
| Cricetinae | 2 | 2013 | 192 | 0.050 |
Why?
| Chromatography, Liquid | 2 | 2014 | 232 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2003 | 172 | 0.050 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 22 | 0.050 |
Why?
| Attitude | 1 | 2019 | 69 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 304 | 0.040 |
Why?
| Dependovirus | 1 | 2020 | 101 | 0.040 |
Why?
| Uridine Diphosphate Glucuronic Acid | 1 | 2019 | 9 | 0.040 |
Why?
| Intestines | 1 | 2020 | 176 | 0.040 |
Why?
| Malate Dehydrogenase | 1 | 2018 | 8 | 0.040 |
Why?
| Risk | 1 | 2019 | 320 | 0.040 |
Why?
| Pharmacists | 1 | 2019 | 144 | 0.040 |
Why?
| Glucuronosyltransferase | 1 | 2019 | 126 | 0.040 |
Why?
| Vascular Stiffness | 1 | 2018 | 18 | 0.040 |
Why?
| Sex Factors | 1 | 2020 | 691 | 0.040 |
Why?
| Cyclohexanols | 1 | 2017 | 21 | 0.040 |
Why?
| PC12 Cells | 1 | 2017 | 24 | 0.040 |
Why?
| Cell Death | 1 | 2017 | 181 | 0.030 |
Why?
| Dopamine Agents | 1 | 2016 | 17 | 0.030 |
Why?
| Microvessels | 1 | 2016 | 29 | 0.030 |
Why?
| Receptors, Dopamine D4 | 1 | 2016 | 10 | 0.030 |
Why?
| Glutathione | 1 | 2017 | 295 | 0.030 |
Why?
| Cattle | 1 | 2016 | 210 | 0.030 |
Why?
| Necrosis | 1 | 2016 | 176 | 0.030 |
Why?
| HEK293 Cells | 1 | 2016 | 222 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 1816 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 1557 | 0.030 |
Why?
| Vesicular Monoamine Transport Proteins | 1 | 2014 | 47 | 0.030 |
Why?
| Nitric Oxide | 1 | 2016 | 253 | 0.030 |
Why?
| MicroRNAs | 1 | 2018 | 353 | 0.030 |
Why?
| Liver | 1 | 2020 | 1115 | 0.030 |
Why?
| Paper | 1 | 2013 | 15 | 0.030 |
Why?
| Capsules | 1 | 2013 | 30 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Powders | 1 | 2013 | 26 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Mitochondria | 1 | 2017 | 402 | 0.030 |
Why?
| Solid Phase Extraction | 1 | 2013 | 12 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| Arkansas | 1 | 2019 | 1977 | 0.030 |
Why?
| Conditioning, Classical | 1 | 2013 | 33 | 0.030 |
Why?
| Drug Design | 1 | 2013 | 120 | 0.030 |
Why?
| Drug Partial Agonism | 1 | 2012 | 6 | 0.030 |
Why?
| Drug Antagonism | 1 | 2012 | 7 | 0.030 |
Why?
| Cell Proliferation | 1 | 2016 | 1007 | 0.030 |
Why?
| Pregnancy | 1 | 2019 | 2607 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 46 | 0.020 |
Why?
| Cell Membrane | 1 | 2012 | 248 | 0.020 |
Why?
| Drug Evaluation, Preclinical | 1 | 2011 | 144 | 0.020 |
Why?
| Molecular Targeted Therapy | 1 | 2011 | 119 | 0.020 |
Why?
| Fluoroacetates | 1 | 2009 | 1 | 0.020 |
Why?
| Iodobenzenes | 1 | 2009 | 1 | 0.020 |
Why?
| Trifluoroacetic Acid | 1 | 2009 | 1 | 0.020 |
Why?
| Cyclization | 1 | 2009 | 5 | 0.020 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 8 | 0.020 |
Why?
| Appetite Depressants | 1 | 2009 | 9 | 0.020 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 15 | 0.020 |
Why?
| Alfentanil | 1 | 2009 | 2 | 0.020 |
Why?
| Capsaicin | 1 | 2009 | 15 | 0.020 |
Why?
| Central Nervous System Agents | 1 | 2009 | 11 | 0.020 |
Why?
| Benzimidazoles | 1 | 2009 | 48 | 0.020 |
Why?
| Pruritus | 1 | 2009 | 44 | 0.020 |
Why?
| Hot Temperature | 1 | 2009 | 207 | 0.020 |
Why?
| Respiratory Insufficiency | 1 | 2009 | 113 | 0.020 |
Why?
| Problem Solving | 1 | 2006 | 43 | 0.020 |
Why?
| Attention | 1 | 2006 | 175 | 0.020 |
Why?
| Learning | 1 | 2006 | 158 | 0.020 |
Why?
|
|
Fantegrossi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|